Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyTACTIC: Targeted Therapies in Advanced Solid Tumors
NCT04632992Phase 2Completed
- Sponsor
- Genentech
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of entrectinib, inavolisib, alectinib, ipatasertib, atezolizumab in solid tumor (advanced stage), sponsored by Genentech. Started Jan 2021; status: completed.
02
Drugs
entrectinibinavolisibalectinibipatasertibatezolizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04632992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632992.